Adriamycin & cyclophosphamide (AC) followed by docetaxel (D) versus AC followed by paclitaxel (P) in operable node positive breast cancer

被引：0
|
作者：
Abdel-Halim, I. [1 ]
Ei-Sadda, W. [1 ]
机构：
[1] Mansoura Univ, Sch Med, Mansoura, Egypt
来源：
BREAST | 2011年 / 20卷
关键词：
D O I：
10.1016/S0960-9776(11)70216-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [1] Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
    Hong, Woo Sung
    Jeon, Ja Young
    Kang, Seok Yun
    Jung, Yong Sik
    Kim, Ji Young
    Ahn, Mi Sun
    Kang, Doo Kyoung
    Kim, Tae Hee
    Yim, Hyun Ee
    An, Young-Sil
    Park, Rae Woong
    Kim, Ku Sang
    [J]. JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2013, 85 (01): : 7 - 14
  • [2] Efficacy and safety profile of the adriamycin/cyclophosphamide (AC) followed by docetaxel/cisplatin (DC) in locally advanced breast cancer
    Abdelhamid, T.
    Saber, M.
    Gaber, A. Abdel-Samie
    Selim, M.
    Youssef, O.
    Salama, A.
    Eldin, N. Aly
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer
    Swain, Sandra M.
    Tang, Gong
    Geyer, Charles E.
    Rastogi, Priya
    Atkins, James Norman
    Donnellan, Paul P.
    Fehrenbacher, Louis
    Azar, Catherine A.
    Robidoux, Andre
    Polikoff, Jonathan
    Brufsky, Adam
    Biggs, David D.
    Levine, Edward A.
    Zapas, John L.
    Provencher, Louise
    Perez, Edith A.
    Paik, Soonmyung
    Costantino, Joseph P.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
    Ishikawa, Takashi
    Shimizu, Satoru
    Katayama, Kiyofumi
    Chishima, Takashi
    Hamaguchi, Yohei
    Doi, Takako
    Tanabe, Mikiko
    Kasahara, Akio
    Yamaguchi, Naotaka
    Narui, Kazutaka
    Ohta, Ikuko
    Matsumoto, Chizuru
    Shimizu, Daisuke
    Kito, Ayako
    Suda, Takashi
    Inaba, Masaaki
    Asaga, Taro
    Momiyama, Nobuyoshi
    Ichikawa, Yasushi
    Yoshimoto, Masataka
    Morita, Satoshi
    Shimada, Hiroshi
    [J]. ANTICANCER RESEARCH, 2009, 29 (05) : 1515 - 1520
  • [5] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
    Iwase, S.
    Yamamoto, D.
    Kitamura, K.
    Odagiri, H.
    Teramoto, S.
    Ohtani, S.
    Doi, T.
    Kinebuchi, K.
    Kuroda, Y.
    Nagumo, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer
    Roy, C.
    Choudhury, K. B.
    Pal, M.
    Saha, A.
    Bag, S.
    Banerjee, C.
    [J]. INDIAN JOURNAL OF CANCER, 2012, 49 (03) : 266 - 271
  • [7] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [8] Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
    Daniel Mendoza-Posada
    Teresa Vela-Chavez
    Enrique Bargallo-Rocha
    Nestor Villafañe
    Carlos Gamboa-Vignole
    Claudia Arce
    [J]. BMC Cancer, 7 (Suppl 1)
  • [9] Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: Results of a feasibility study
    Cardoso, F
    Ferreira, AF
    Crown, J
    Dolci, S
    Paesmans, M
    Riva, A
    Di Leo, A
    Piccart, MJ
    [J]. ANTICANCER RESEARCH, 2001, 21 (1B) : 789 - 795
  • [10] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    [J]. CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
12345